CN Patent
CN105859641B — 喹唑啉巴豆基化合物二马来酸盐的晶体及其制备方法和用途
Assigned to HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE Co Ltd · Expires 2018-11-16 · 8y expired
What this patent protects
本发明公开了一种式I所示化合物的二马来酸盐晶型K、晶型E、晶型F和晶型G,并公开了它们的制备方法和用途。所述晶型K、晶型E、晶型F和晶型G具有优良的储存稳定性和溶解性,更适合作为制剂原料使用。
USPTO Abstract
本发明公开了一种式I所示化合物的二马来酸盐晶型K、晶型E、晶型F和晶型G,并公开了它们的制备方法和用途。所述晶型K、晶型E、晶型F和晶型G具有优良的储存稳定性和溶解性,更适合作为制剂原料使用。
Drugs covered by this patent
- Vizimpro (Dacomitinib) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.